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The aim of this present study was to synthesize 2-substituted and 1,2-disubstituted benzimidazole
derivatives to investigate their antibacterial diversity for possible future drug design. The structure-
based design of precursors 2-(1H-benzimidazol-2-yl)aniline 1, 2-(3,5-dinitro phenyl)-1H-
benzimidazole 3 and 2-benzyl-1H-benzimidazole 5 were achieved by the condensation reaction of o-
phenylenediamine with anthranilic acid, 3,5-dinitrophenylbenzoic acid, and phenylacetic acid, respec-
tively. The precursors 1, 3 and 5, upon reaction with six different electrophile-releasing agents, furnished
the corresponding 2-substituted benzimidazole, 2a-f and 1,2-disubstituted benzimidazole derivatives
4a-f and 6a-f, respectively. The structural identity of the targeted compounds was authenticated by ele-
mental analytical data and spectral information from FT-IR, UV, 1H, and 13C NMR. The outcome of the
findings from the in vitro screening unveiled 2-benzyl-1-(phenylsulfonyl)-1H-benzimidazole 6b as the
most active derivative with lowest MIC value of 15.63 mg/mL.
 2017 Production and hosting by Elsevier B.V. on behalf of Cairo University. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
From time to time, heterocyclic templates have continued to
gain respect and much interest among the medicinal chemists,
because of their numerous therapeutic applications and effective
reported druggability [1]. Benzimidazole is a heterocyclic aromatic
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ment of theory in heterocyclic chemistry and organic synthesis
[2]. Benzimidazole is a strongly acidic compound with a pKa of
12.75, while its conjugated acid has a pKa of 5.68, which is less
basic than imidazole. Benzimidazole is readily prepared by [4+1]-
cycloaddition of o-phenylenediamine with a one carbon donor
source in the presence of various heterogeneous catalysts [3], such
as H2O2/HCl [4], H2O2/CAN [5], H2O/HCl [6], H2O2/Fe(NO3)3 [7], and
H2O2/Bu4NI [8] as efficient oxidative couples. In healthful analysis,
the synthesis of novel benzimidazole derivatives remains a focus
[9]. Diverse synthetic efforts for accessing benzimidazole deriva-
tives have been documented, however, the commonest technique
involves the reaction of o-phenylenediamine with alkanoic acids.
From the evaluation of the works of various researchers, benzimi-
dazole derivatives have been reported to possess antimalarial [10],
anticancer [11], antimicrobial [12,13], antioxidant [14], and anti-
convulsant [15] activities among others. Some derivatives of benz-
imidazole are well known in corrosion studies and their corrosion
inhibition efficiencies are related to their adsorption properties
[16].
The outbreak of new diseases and the increase in population of
drug resistant strains of bacteria, such as methicillin-resistant Sta-
phylococcus aureus [17], vancomycin-resistant Enterococci [18],
ampicillin-resistant Enterobacter aerogenes [19], gentamicin-
resistant Escherichia coli [20], and chloroquine-resistant Plasmod-
ium falciparum [21], have posed great challenges to life and wellbe-
ing of mankind. Based on the existence of antidrug multi-resistant
bacteria strains [22], the occurrence of side effects to commercially
available drugs [23], adverse drug reaction in elderly patient [24],
the emergence of new diseases, and global health threat that have
resulted in high mortality rate [25]; it has become highly impera-
tive to consistently and continuously engage in the synthetic
preparation of novel heterocyclic templates as highly dynamic bio-
logically active substances for therapeutic uses. Therefore, it is
beneficial to design some 2-substituted- and 1,2-disubstituted
benzimidazole derivatives by ecofriendly method so as to examine
their antimicrobial properties for possible future drug
development.Material and methods
Chemical compounds and reagents were purchased from
Sigma-Aldrich Chemicals (St. Louis, Missouri, USA) apart from
Tetrahydrofuran (THF), benzenesulfonyl chloride, and anthranilic
acid which were supplied by the British Drug Houses (Poole, Dor-
set, England). All these compounds were then made available by
Department of Chemistry, Covenant University for research use.
All the chemicals are pure and they were used directly without fur-
ther purification. The synthesized heterocyclic frameworks were
evaluated for their melting point determination using Stuart
equipment and the value obtained were recorded directly. Bruker
fourier-transform (ft-ir) spectrophotometer was utilized to obtain
infrared data. The UV spectra of the solution of the compounds
in THF were run in UV Genesys 10 s. The 1H and 13C nuclear mag-
netic resonance of the heterocycles were NMR Bruker DPX 400
spectrometer at 400 MHz and 100 MHz, respectively in DMSO-d6.
The reference utilized was Tetramethylsilane (TMS). The reaction
progress as well as the level of purity was routinely checked and
monitored with Thin Layer Chromatography (TLC) using CHCl3/
CH3OH (9:1, v/v) eluent. After reaction was completed, solvents
were evaporated under reduced pressure using IKA RV 10 Rotary
evaporator. In a situation where more than one spots were
observed, column chromatography was carried out to get a pure
compound.2-(1H-Benzimizadol-2-yl)aniline as precursor 1
o-Phenylene diamine (15.00 g, 140.00 mmol) was weighed and
dissolved in 150 mL of ethanol in a round- bottomed flask. It was
stirred for 5 min with the aid of magnetic stirrer after which
anthranilic acid (19.20 g, 140.00 mmol) was gradually tipped into
the solution followed by the addition of a catalytic amount of NH4-
Cl (0.75 g, 14.00 mmol). The resulting solution was then heated
under reflux at 60–70 C for 2 h. The TLC was utilized to ascertain
the progress of reaction. Upon completion, the resulting solution
was allowed to cool down. The flask content was evaporated to
dryness and triturated with ice-cold water. The solid mass formed
was separated by suction filtration to furnish 2-(1H-benzimizadol-
2-yl)aniline 1 (72.68%), mp = 85–87 C, colour = gray. 1H NMR
(400 MHz, DMSO-d6) dH: 4.50 (s-br, 2H, NH2), 6.37–6.39 (dd,
J1 = 4.54 Hz, J2 = 8.80 Hz, 1H, Ph-H), 6.49–6.50 (dd, J1 = 4.21 Hz,
J2 = 8.87 Hz, 1H, Ph-H), 6.84–6.86 (d, J = 8.80 Hz, 1H, Ph-H), 7.12–
7.14 (d, J = 8.00 Hz, 1H, Ph-H), 7.39–7.41 (m, 2H, Ph-H), 7.59–7.63
(d, J = 8.87 Hz, 1H, Ph-H). 13C NMR (100 MHz, DMSO-d6) dC:
109.6, 115.2 (2  CH), 116.9, 119.4, 123.1 (2  CH), 125.5, 129.7,
141.9 (2  C), 145.1, 155.0 ppm. kmax in nm (log emax): 218
(4.2741), 253 (4.3096), 326 (3.6434). FT-IR m in cm1: 3424
(NAH of NH2), 3422 (NAH of NH2), 3405 (NAH), 1620 (C@C aro-
matic). Anal. Calcd for C13H11N3 (209.25): C, 74.62; H, 5.30; N,
20.08%. Found: C, 74.80; H, 5.47; N, 19.96%.
Overall protocol towards accessing 2-substituted benzimidazole 2a-f
Precursor 1 (4.00 g, 19.10 mmol) was dissolved in 20 mL of
tetrahydrofuran (THF) in a round-bottomed flask at room temper-
ature. The medium was basified by the addition of Na2CO3 (4.06 g,
38.30 mmol) and cooled to 0–5 C in ice bath. The corresponding
electrophile-releasing substrate a-f (19.10 mmol) was then added
and the reacting mixture was maintained on ice bath for additional
15 min after which the medium was warmed up to room temper-
ature and stirred there for 24 h. Monitoring of reaction progress
was conducted using TLC and upon reaction completion, the sol-
vent was evaporated at reduced pressure using rotary evaporator.
Cold water was added to the resulting mass, filtered by suction,
and air-dried to afford crude product which upon column purifica-
tion afforded 2-substituted benzimidazole derivatives 2a-f.
N-(2-(1H-Benzimidazole-2-yl)phenyl) acetamide 2a
When a = acetyl chloride, yield 57.70%, mp = 253–255 C, col-
our = gray. 1H NMR (400 MHz, DMSO-d6) dH: 2.67 (s, 3H, CH3ACO),
6.36–6.39 (dd, J1 = 4.58 Hz, J2 = 8.82 Hz, 1H, PhAH), 6.51–6.52 (dd,
J1 = 4.18 Hz, J2 = 8.89 Hz, 1H, PhAH), 6.86–6.88 (d, J = 8.82 Hz, 1H,
PhAH), 7.13–7.15 (d, J = 8.00 Hz, 1H, PhAH), 7.39–7.43 (m, 2H,
PhAH), 7.62–7.65 (d, J = 8.89 Hz, 1H, PhAH). 13C NMR (100 MHz,
DMSO-d6) dC: 26.4 (CH3), 109.6, 115.2 (2  CH), 116.8, 119.6,
123.6 (2  CH), 125.6, 129.8, 141.7 (2  C), 145.3, 156.1, 175.4
(C@O) ppm. kmax in nm (log emax): 218 (4.2988), 248 (4.5563),
323 (3.8261), 464 (2.4771). FT-IR m in cm1: 3405 (NAH), 1699
(C@O). Anal. Calcd for C15H13N3O (251.11): C, 71.70; H, 5.21; N,
16.72%. Found: C, 71.88; H, 5.09; N, 16.89%.
N-(2-(1H-Benzimidazole-2-yl)phenyl)benzenesulfonamide 2b
When b = benzenesulfonyl chloride, yield 97.21%, mp = N.D.
(Oily), colour = black. 1H NMR (400 MHz, DMSO-d6) dH: 6.35–6.38
(m, 3H, PhAH), 6.46–6.49 (m, 2H, PhAH), 6.84–6.86 (d,
J = 7.16 Hz, 2H, PhAH), 7.11–7.14 (d, J = 11.96 Hz, 2H, PhAH),
7.40–7.42 (m, 2H, PhAH), 7.62–7.65 (d, J = 11.88 Hz, 2H, PhAH).
13C NMR (100 MHz, DMSO-d6) dC: 109.8, 115.3 (2  CH), 116.9,
119.5, 123.2 (2  CH), 125.6, 127.5 (2  CH), 128.9, 129.8
O.O. Ajani et al. / Journal of Advanced Research 8 (2017) 703–712 705(2  CH), 131.9, 154.8, 139.7, 141.6 (2  C), 145.3 ppm. kmax in nm
(log emax): 221 (4.6609), 251 (4.7332), 317 (4.2878), 428 (3.9294).
FT-IR m in cm1: 3405 (NAH), 3266 (NAH), 1620 (C@C aromatic),
1575 (C@N imine), 1376 (SO2), 1185 (SO2). Anal. Calcd for C19H15-
N3O2S (349.09): C, 65.31; H, 4.33; N, 12.03%. Found: C, 65.20; H,
4.15; N, 11.83%.
N-(2-(1H-Benzimidazole-2-yl)phenyl)-4-methylbenzenesulfonamide
2c
When c = p-toluenesulfonyl chloride, yield 80.03%, mp = N.D.
(Oily), colour = brown. 1H NMR (400 MHz, DMSO-d6) dH: 2.80 (s,
3H, CH3-Ar), 6.36–6.39 (m, 3H, PhAH), 6.49–6.51 (m, 2H, PhAH),
6.84–6.86 (d, J = 7.04 Hz, 1H, PhAH), 7.11–7.14 (d, J = 11.96 Hz,
2H, PhAH), 7.40–7.42 (m, 2H, PhAH), 7.62–7.65 (d, J = 11.88 Hz,
2H, PhAH). 13C NMR (100 MHz, DMSO-d6) dC: 21.3 (CH3), 109.8,
115.3 (2  CH), 116.9, 119.5, 123.2 (2  CH), 125.6, 127.3
(2  CH), 129.1, 129.8 (2  CH), 131.9, 139.7, 141.8 (2  C), 145.3,
155.0 ppm. kmax in nm (log emax): 212 (4.6343), 233 (5.2124),
311 (4.6750). FT-IR m in cm1: 3407 (NAH), 3263 (NAH), 1377
(SO2), 1187 (SO2). Anal. Calcd for C20H17N3O2S (363.43): C, 66.10;
H, 4.71; N, 11.56%. Found: C, 65.95; H, 4.63; N, 11.75%.
2-(1H-Benzimidazol-2-yl)-N-(3-chlorobenzyl)aniline 2d
When d = 3-chlorobenzyl chloride, yield 87.90%, mp = N.D.
(Oily), colour = black. 1H NMR (400 MHz, DMSO-d6) dH: 3.73 (s,
2H, CH2), 6.31–6.35 (m, 3H, PhAH), 6.48–6.50 (m, 2H, PhAH),
6.84–6.87 (d, J = 8.00 Hz, 1H, PhAH), 7.11–7.14 (d, J = 11.96 Hz,
2H, PhAH), 7.61–7.63 (d, J = 7.96 Hz, 2H, PhAH), 7.92–7.94 (d,
J = 7.72 Hz, 1H, PhAH), 8.21 (s, 1H, PhAH). 13C NMR (100 MHz,
DMSO-d6) dC: 48.2 (CH2), 112.3, 114.1, 115.1 (2  CH), 117.4,
123.2 (2  CH), 125.0, 125.4, 126.1, 126.8, 129.3, 129.9, 132.2,
134.3, 141.8 (2  C), 145.4, 154.8 ppm. kmax in nm (log emax): 224
(5.0026), 251 (4.9633), 302 (4.7279). FT-IR m in cm1: 3460, 3354
(NAH), 3107 (CAH aromatic), 2924 (CH aliphatic), 2854 (CH ali-
phatic), 1624 (C@C Aromatic), 1581 (C@N). Anal. Calcd for C20H16-
N3Cl (333.81): C, 71.96; H, 4.84; N, 12.59%. Found: C, 72.14; H,
5.02; N, 12.38%.
5-((2-(1H-Benzimidazole-2-yl)phenyl)amino)pyrimidine-2,4(1H,3H)-
dione 2e
When e = 5-bromouracil, yield 83.29%, mp > 300 C, colour = -
brown. 1H NMR (400 MHz, DMSO-d6) dH: 6.36–6.39 (m, 1H. PhAH),
6.50–6.52 (m, 1H. PhAH), 6.83–6.86 (d, J = 11.88 Hz, 1H, PhAH),
7.11–7.13 (d, J = 8.00 Hz, 2H, PhAH), 7.39–7.43 (m, 2H, PhAH),
7.62–7.65 (d, J = 11.88 Hz, 1H, PhAH), 8.37–8.41 (d, J = 13.92 Hz,
1H, PhAH), 11.02 (s, IH, NH), 11.56 (s, 1H, NH). 13C NMR
(100 MHz, DMSO-d6) dC: 109.2, 110.6, 115.6 (2  CH), 119.3,
123.1 (2  CH), 125.3, 125.7, 126.2, 129.4, 141.8 (2  C), 145.0,
152.5, 169.0 (C@O), 169.8 (C@O) ppm. kmax in nm (log emax): 202
(4.5646), 224 (4.9854), 254 (5.1392). FT-IR (mmax in cm1): 3460,
3354 (NAH), 3107 (CAH aromatic), 2924 (CH aliphatic), 2854
(CH aliphatic), 1624 (C@C aromatic), 1581 (C@N). Anal. Calcd for
C17H13N5O2 (319.32): C, 63.94; H, 4.10; N, 21.93%. Found: C,
63.90; H, 3.99; N, 22.01%.
N-(2-(1H-Benzimidazole-2-yl)phenyl)benzene-1,4-diamine 2f
When f = 4-chloroaniline, yield 80.74%, mp > 300 C, colour = -
gray. 1H NMR (400 MHz, DMSO-d6) dH: 5.32 (s, 2H, NH2), 6.33–
6.38 (m, 2H, PhAH), 6.49–6.53 (m, 2H, PhAH), 6.83–6.86 (d,
J = 9.92 Hz, 1H, PhAH), 7.11–7.14 (d, J = 10.48 Hz, 2H, PhAH),
7.39–7.41 (d, J = 8.50 Hz, 2H, PhAH), 7.59–7.62 (d, J = 10.48 Hz,
2H, PhAH). 13C NMR (100 MHz, DMSO-d6) dC: 109.8, 115.3(2  C), 117.2 (2  CH), 118.1, 119.5, 121.1 (2  CH), 123.0
(2  CH), 125.6, 129.8, 132.2, 137.9, 140.9, 141.8 (2  C),
154.8 ppm. kmax in nm (log emax): 224 (5.0228), 254 (1.9881),
308 (4.5453). FT-IR (mmax in cm1): 3436 (NAH of 1 amine),
3406 (NAH of 1 amine), 3330 (NAH of 2 amine), 3060 (CAH aro-
matic), 1613 (C@C aromatic), 1577 (C@N). Anal. Calcd for C19H16N4
(300.36): C, 75.98; H, 5.37; N, 18.65%. Found: C, 76.09; H, 5.40; N,
18.45%.2-(3,5-Dinitrophenyl)-1H-benzimidazole as precursor 3
Procedure for the synthesis of precursor 1 was repeated for the
reaction of o-phenylenediamine with 3,5-dinitrophenylbenzoic
acid to afford precursor 3 (90.07%), mp = 177–179 C, colour = yel-
low. 1H NMR (400 MHz, DMSO-d6) dH: 7.40–7.42 (d, J = 8.00 Hz, 1H,
PhAH), 7.44–7.46 (d, J = 8.00 Hz, 1H, PhAH), 7.72–7.74 (t,
J = 7.58 Hz, 1H, PhAH), 7.94–7.96 (m, 1H, PhAH), 8.64 (s, 2H,
PhAH), 8.85 (s, 1H, ArAH). 13C NMR (100 MHz, DMSO-d6) dC:
115.2 (2  CH), 125.8, 128.7 (2  CH), 129.4 (2  CH), 134.8,
144.2 (2  C), 150.7 (2  C), 156.1 ppm. kmax in nm (log emax):
218 (4.6522), 248 (4.6365). FT-IR (mmax in cm1): 3349 (NAH),
3172 (CAH aromatic), 3101 (CAH aromatic), 1606 (C@C), 1572
(C@N), 1543 (NO2 asym.), 1344 (NO2 sym.). Anal. Calcd for
C13H8N4O4 (284.22): C, 55.13; H, 2.49; N, 19.78%. Found: C,
54.98; H, 2.54; N, 19.92%.Overall protocol towards accessing 1,2-disubstituted-1H-
benzimidazole 4a-f
Similar procedure for 2a-f was repeated herein using 2-(3,5-
dinitrophenyl)-1H-benzimidazole 3 as the precursor which reacted
with substrates a-f to afford 1-substituted-2-(3,5-dinitrophenyl)-
1H-benzimidazoles 4a-f.1-(2-(3,5-Dinitrophenyl)-1H-benzimidazole-1-yl)ethanone 4a
Yield 72.58%, mp = 250–252 C, colour = brown. 1H NMR
(400 MHz, DMSO-d6) dH: 2.59 (s, 3H, CH3ACO), 7.40–7.42 (d,
J = 8.00 Hz, 1H, PhAH), 7.44–7.46 (d, J = 8.00 Hz, 1H, PhAH), 7.72–
7.74 (t, J = 7.56 Hz, 1H, PhAH), 7.94–7.96 (m, 1H, PhAH), 8.64 (s,
2H, PhAH), 8.85 (s, 1H, PhAH). 13C NMR (100 MHz, DMSO-d6) dC:
28.9 (CH3), 116.6 (2  CH), 126.1, 128.9 (2  CH), 129.7 (2  CH),
135.0, 144.3 (2  C), 150.5 (2  C), 156.3, 174.1 (C@O) ppm. kmax
in nm (log emax): 218 (4.3729), 248 (4.3050). FT-IR (mmax in
cm1): 3106 (CAH aromatic), 2854 (CAH aliphatic), 1699 (C@O
amide), 1622 (C@C), 1580 (C@N), 1541 (NO2asym.), 1346 (NO2
sym.). Anal. Calcd for C15H10N4O5 (326.26): C, 55.22; H, 3.09; N,
17.17%. Found: C, 55.13; H, 2.89; N, 17.08%.2-(3,5-Dinitrophenyl)-1-(phenylsulfonyl)-1H-benzimidazole 4b
Yield 62.77%, mp > 300 C, colour = gray. 1H NMR (400 MHz,
DMSO-d6) dH: 7.15–7.19 (m, 5H, PhAH), 7.40–7.46 (m, 2H, PhAH),
7.72–7.74 (t, J = 7.60 Hz, 1H, PhAH), 7.94–7.96 (m, 1H, PhAH), 8.64
(s, 2H, PhAH), 8.85 (s, 1H, PhAH). 13C NMR (100 MHz, DMSO-d6)
dC: 116.6 (2  CH), 119.6 (2  CH), 126.1, 128.9 (2  CH), 129.7
(2  CH), 132.5, 135.0 (2  C), 137.5 (2  CH), 144.3 (2  C),
150.5, 152.0, 156.3 ppm. kmax in nm (log emax): 215 (3.9395), 251
(4.1492). FT-IR (mmax in cm1): 3050 (CAH aromatic), 2855 (CAH
aliphatic), 1620 (C@C), 1580 (C@N), 1541 (NO2asym.), 1376
(SO2), 1346 (NO2 sym.), 1185 (SO2 2nd band). Anal. Calcd for C19-
H12N4O6S (434.39): C, 53.77; H, 2.85; N, 13.20%. Found: C, 53.95;
H, 3.03; N, 13.31%.
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Yield 98.77%, mp = 112 C, colour = brown. 1H NMR (400 MHz,
DMSO-d6) dH: 2.60 (s, 3H, CH3AAr), 6.90–6.92 (d, J = 8.00 Hz, 2H,
PhAH), 7.15–7.17 (d, J = 8.00 Hz, 2H, PhAH), 7.40–7.44 (m, 2H,
PhAH), 7.73–7.75 (t, J = 7.54 Hz, 1H, PhAH), 7.93–7.95 (m, 1H,
PhAH), 8.60 (s, 2H, PhAH), 8.84 (s, 1H, PhAH). 13C NMR
(100 MHz, DMSO-d6) dC: 21.7 (CH3), 116.6 (2  CH), 119.6
(2  CH), 124.8, 156.3, 152.1, 150.5, 144.3 (2  C), 137.5 (2  CH),
135.0, 132.5, 129.5 (2  CH), 126.0, 128.9 (2  CH) ppm. kmax in
nm (log emax): 242 (4.6138). FT-IR (mmax in cm1): 3105 (CAH aro-
matic), 2852 (CAH aliphatic), 1620 (C@C), 1575 (C@N), 1540 (NO2
asym.), 1377 (SO2), 1345 (NO2 sym.). Anal. Calcd for C20H14N4O6S
(438.41): C, 54.79; H, 3.22; N, 12.78%. Found: C, 54.62; H, 3.16;
N, 12.94%.1-(3-Chlorobenzyl)-2-(3,5-dinitrophenyl-1H-benzimidazole 4d
Yield 71.16%, mp > 300 C, colour = black. 1H NMR (400 MHz,
DMSO-d6) dH: 3.72 (s, 2H, CH2AAr), 7.11–7.14 (m, 1H, PhAH),
7.25–7.27 (d, J = 7.56 Hz, 2H, PhAH), 7.40–7.46 (m, 2H, PhAH),
7.72–7.74 (t, J = 7.60 Hz, 1H, PhAH), 7.94–7.96 (d, J = 7.22 Hz, 1H,
PhAH), 8.21 (s, 1H, PhAH), 8.64 (s, 2H, PhAH), 8.85 (s, 1H, PhAH).
13C NMR (100 MHz, DMSO-d6) dC: 48.0 (CH2), 115.2, 116.2 (2  CH),
119.2, 125.1, 126.1, 128.9 (2  CH), 129.7 (2  CH), 130.0, 135.0,
139.1, 144.0 (2  C), 150.4 (2  C), 156.1 ppm. kmax in nm (log
emax): 212 (3.7076), 248 (4.1986), 467 (2.6020), 470 (2.6020). FT-
IR (mmax in cm1): 2924, 2854 (CH aliphatic), 1612 (C@C Aromatic),
1584 (C@N imine), 1501 (NO2 asym.). Anal. Calcd for C20H13N4O4Cl
(408.79): C, 58.76; H, 3.21; N, 13.71%. Found: C, 58.88; H, 3.32; N,
13.89%.5-(2-(3,5-Dinitrophenyl)-1H-benzimidazol-1-yl)pyrimidine-2,4
(1H,3H)-dione 4e
Yield 61.04%, mp > 300 C, colour = gray. 1H NMR (400 MHz,
DMSO-d6) dH: 7.40–7.42 (t, J = 7.24 Hz, 1H, PhAH), 7.44–7.46 (m,
1H, PhAH), 7.72–7.74 (d, J = 8.00 Hz, 2H, PhAH), 7.94–7.96 (s, 1H,
PhAH), 8.64 (s, 2H, PhAH), 8.85 (s, 1H, PhAH), 11.05 (s, IH, NH),
11.55 (s, 1H, NH). 13C NMR (100 MHz, DMSO-d6) dC: 116.6
(2  CH), 126.1, 128.9 (2  CH), 129.7 (2  CH), 135.0, 138.7,
140.1, 144.3 (2  C), 150.5 (2  C), 156.3, 169.0 (C@O), 169.7
(C@O) ppm. kmax in nm (log emax): 220 (4.0234), 242 (4.8730),
311 (4.0790). FT-IR (mmax in cm1): 3362 (NAH), 3217 (NAH),
3050 (CAH aromatic), 1685 (C@O amide), 1612 (C@C aromatic),
1575 (C@N), 1536 (NO2 asym), 1344 (NO2 sym.). Anal. Calcd for
C17H10N6O6 (394.30): C, 51.78; H, 2.56; N, 21.31%. Found: C,
51.97; H, 2.69; N, 21.51%.4-(2-(3,5-Dinitrophenyl)-1H-benzimidazole-1-yl)aniline 4f
Yield 66.85%, mp > 300 C, colour = gray. 1H NMR (400 MHz,
DMSO-d6) dH: 4.50 (s, 2H, NH2), 6.90–6.92 (d, J = 8.00 Hz, 2H,
PhAH), 7.15–7.17 (d, J = 8.00 Hz, 2H, PhAH), 7.40–7.44 (m, 2H,
PhAH), 7.73–7.76 (t, J = 7.84 Hz, 1H, PhAH), 7.93–7.96 (m, 1H,
PhAH), 8.69 (s, 2H, PhAH), 8.90 (s, 1H, PhAH). 13C NMR
(100 MHz, DMSO-d6) dC: 115.2, 116.6 (2  CH), 118.3 (2  CH),
125.3, 126.1, 128.9 (2  CH), 129.7 (2  CH), 135.0, 144.1 (2  C),
147.0, 147.8, 150.5 (2  C), 155.4 ppm. kmax in nm (log emax): 235
(5.4130), 302 (4.8040). FT-IR (mmax in cm1): 3472 (NAH), 3363
(NAH), 3214, 1620 (C@C aromatic), 1536 (NO2 asym), 1321, 1377
(NO2sym). Anal. Calcd for C19H13N5O4 (375.34): C, 60.80; H, 3.49;
N, 18.66%. Found: C, 61.00; H, 3.68; N, 18.84%.2-Benzyl-1H-benzimidazole as precursor 5
Procedure for the synthesis of precursor 1 was repeated for the
reaction of o-phenylenediamine with phenyl acetic acid to afford
precursor 5 (79.12%), mp = 108–110 C, colour = brown. 1H NMR
(400 MHz, DMSO-d6) dH: 3.56 (s, 2H, CH2AAr), 6.35–6.38 (dd,
J1 = 3.48 Hz, J2 = 9.12 Hz, 1H, PhAH), 6.48–6.50 (dd, J1 = 3.48 Hz,
J2 = 8.00 Hz, 1H, PhAH), 7.12 (s, 5H, PhAH), 7.24–7.26 (d,
J = 9.12 Hz, 1H, PhAH), 7.29–7.31 (d, J = 8.00 Hz, 1H, PhAH). 13C
NMR (100 MHz, DMSO-d6) dC: 34.9 (CH2), 115.2 (2  CH), 123.4
(2  CH), 125.8, 128.7 (2  CH), 129.4 (2  CH), 136.9, 138.8
(2  C), 142.7 ppm. kmax in nm (log emax): 257 (5.4181), 275
(5.4133), 314 (4.4842). FT-IR (mmax in cm1): 3415 (NAH), 2924
(CAH aliphatic), 2854 (CAH aliphatic), 1638 (C@C), 1587 (C@N
imine). Anal. Calcd for C14H12N2 (208.26): C, 80.74; H, 5.81; N,
13.45%. Found: C, 80.80; H, 6.01; N, 13.44%.
Overall protocol towards accessing 1,2-disubstituted-1H-
benzimidazole 6a-f
Similar procedure for the synthesis of 2a-f was repeated herein
using 2-benzyl-1H-benzimidazole 5 as the precursor which reacted
with substrates a-f to afford 1-substituted-2-benzyl-1H-
benzimidazoles 6a-f.
1-(2-Benzyl-1H-benzimidazole-1-yl)ethanone 6a
Yield 90.11%, mp = N.D. (Oily), colour = black. 1H NMR
(400 MHz, DMSO-d6) dH: 2.67 (s, 3H, CH3CO), 3.56 (s, 2H, CH2AAr),
6.36–6.39 (dd, J1 = 3.48 Hz, J2 = 9.12Hz, 1H, PhAH), 6.48–6.50 (dd,
J1 = 3.48 Hz, J2 = 8.00Hz, 1H, PhAH), 7.09 (s, 5H, PhAH), 7.24–7.26
(d, J = 9.12 Hz, 1H, PhAH), 7.29–7.31 (d, J = 8.00 Hz, 1H, PhAH).
13C NMR (100 MHz, DMSO-d6) dC: 28.9 (CH3), 34.9 (CH2), 115.2
(2  CH), 123.5 (2  CH), 125.9, 128.7 (2  CH), 129.5 (2  CH),
136.9, 138.9 (2  C), 142.8 ppm. kmax in nm (log emax): 227
(2.2300), 315 (2.5057). FT-IR (mmax in cm1): 2922 (CAH aliphatic),
2855 (CAH aliphatic), 1685 (C@O), 1620 (C@C), 1575 (C@N imine).
Anal. Calcd for C16H14N2O (250.30): C, 76.78; H, 5.64; N, 11.19%.
Found: C, 76.94; H, 5.59; N, 11.00%.
2-Benzyl-1-(phenylsulfonyl)-1H-benzimidazole 6b
Yield 87.48%, mp = N.D. (Oily), colour = black. 1H NMR
(400 MHz, DMSO-d6) dH: 3.56 (s, 2H, CH2AAr), 6.35–6.38 (dd,
J1 = 3.60 Hz, J2 = 9.26 Hz, 1H, PhAH), 6.48–6.50 (dd, J1 = 3.60 Hz,
J2 = 8.00 Hz, 1H, ArAH), 6.91–6.95 (m, 3H, PhAH), 7.12 (s, 5H,
PhAH), 7.13–7.17 (m, 3H, PhAH), 7.22–7.24 (d, J = 9.26 Hz, 1H,
PhAH), 7.30–7.32 (d, J = 8.00 Hz, 1H, PhAH), 7.44–7.46 (d,
J = 8.66 Hz, 2H, PhAH). 13C NMR (100 MHz, DMSO-d6) dC: 34.7
(CH2), 115.2 (2  CH), 123.4 (2  CH), 125.8, 128.1 (2  CH),
128.7 (2  CH), 129.0 (2  CH), 129.9 (2  CH), 133.9, 136.8,
137.9, 138.7 (2  C), 142.9 ppm. kmax in nm (log emax): 215
(4.4669), 254 (4.4540). FT-IR (mmax in cm1): 2922, 2850 (CH ali-
phatic), 1620 (C@C aromatic), 1575 (C@N imine), 1375 (SO2),
1185 (SO2 2nd band). Anal. Calcd for C20H16N2O2S (348.42): C,
68.94; H, 4.63; N, 8.04%. Found: C, 69.00; H, 4.82; N, 7.89%.
2-Benzyl-1-tosyl-1H-benzimidazole 6c
Yield 93.25%, mp = N.D. (Oily), colour = brown. 1H NMR
(400 MHz, DMSO-d6) dH: 2.76 (s, 3H, CH3AAr), 3.56 (s, 2H, CH2AAr),
6.35–6.38 (dd, J1 = 3.60 Hz, J2 = 9.26 Hz, 1H, PhAH), 6.48–6.49 (dd,
J1 = 3.60 Hz, J2 = 8.00 Hz, 1H, PhAH), 6.92–6.94 (d, J = 8.76 Hz, 2H,
PhAH), 7.12 (s, 5H, PhAH), 7.22–7.24 (d, J = 9.26 Hz, 1H, PhAH),
7.30–7.32 (d, J = 8.00 Hz, 1H, PhAH), 7.44–7.46 (d, J = 8.76 Hz, 2H,
PhAH). 13C NMR (100 MHz, DMSO-d6) dC: 21.5(CH3), 34.9 (CH2),
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(2  CH), 129.5 (2  CH), 130.1 (2  CH), 134.7, 136.7, 138.9
(2  C), 139.6, 142.6 ppm. kmax in nm (log emax): 233 (5.3679),
299 (4.7896). FT-IR (mmax in cm1): 2924, 2854 (CH aliphatic),
1648 (C@C aromatic), 1562 (C@N imine), 1376 (SO2), 1185 (SO2
2nd band). Anal. Calcd for C21H18N2O2S (362.44): C, 69.59; H,
5.01; N, 7.73%. Found: C, 69.51; H, 4.88; N, 7.82%.
2-Benzyl-1-(3-chlorobenzyl)-1H-benzimidazole 6d
Yield 91.83%, mp = N.D. (Oily), colour = brown. 1H NMR
(400 MHz, DMSO-d6) dH: 3.42 (s, 2H, CH2AAr), 3.58 (s, 2H, CH2AAr),
6.35–6.38 (dd, J1 = 3.48 Hz, J2 = 9.18 Hz, 1H, PhAH), 6.48–6.50 (dd,
Jm1 = 3.48 Hz, J2 = 8.00 Hz, 1H, PhAH), 7.10 (s, 5H, PhAH), 7.17–
7.19 (dd, J1 = 7.20 Hz, J2 = 7.82 Hz, 1H, PhAH), 7.23–7.25 (d,
J = 9.18 Hz, 1H, PhAH), 7.31–7.33 (d, J = 8.00 Hz, 1H, PhAH), 7.37–
7.38 (d, J = 7.82 Hz, 1H, PhAH), 7.51–7.52 (d, J = 7.20 Hz, 1H, PhAH),
8.21 (s, 1H, PhAH). 13C NMR (100 MHz, DMSO-d6) dC: 33.8 (CH2),
48.0 (CH2), 115.2 (2  CH), 123.4 (2  CH), 125.1 125.6, 125.8,
128.7 (2  CH), 128.9, 129.5 (2  CH), 130.2, 134.4, 136.7, 137.8,
138.9 (2  C), 142.5 ppm. kmax in nm (log emax): 233 (5.3877),
251 (5.0266). FT-IR (mmax in cm1): 2984 (CAH aliphatic), 1646
(C@C). 1565 (C@N), 652 (CACl). Anal. Calcd for C20H17ClN2
(332.83): C, 75.78; H, 5.15; N, 8.42%. Found: C, 75.70; H, 4.01; N,
8.25%.
5-(2-Benzyl-1H-benzimidazole-1-yl)pyrimidine-2,4(1H,3H)-dione 6e
Yield 80.58%, mp = N.D. (Oily), colour = black. 1H NMR
(400 MHz, DMSO-d6) dH: 3.56 (s, 2H, CH2AAr), 6.34–6.37 (dd,
J1 = 3.44 Hz, J2 = 9.18 Hz, 1H, PhAH), 6.48–6.50 (dd, J1 = 3.44 Hz,
J2 = 8.00 Hz, 1H, PhAH), 7.11 (s, 5H, PhAH), 7.23–7.25 (d,
J = 9.18 Hz, 1H, PhAH), 7.30–7.32 (d, J = 8.00 Hz, 1H, PhAH), 7.95–
7.97 (s, 1H, PhAH), 11.05 (s, IH, NH), 11.55 (s, 1H, NH). 13C NMR
(100 MHz, DMSO-d6) dC: 34.8 (CH2), 115.2 (2  CH), 119.9, 123.3
(2  CH), 125.7, 128.7 (2  CH), 129.4 (2  CH), 136.7, 138.5
(2  C), 142.9, 150.0, 169.2 (C@O), 169.7 (C@O) ppm. kmax in nm
(log emax): 218 (4.6532), 248 (4.5775), 293 (4.1399), 437
(3.4914). FT-IR (mmax in cm1): 3360 (NAH), 3217 (NAH), 3050
(CAH aromatic), 1685 (C@O amide), 1615 (C@C aromatic), 1575
(C@N). Anal. Calcd for C18H14N4O2 (318.33): C, 67.91; H, 4.43; N,
17.60%. Found: C, 68.10; H, 4.57; N, 17.77%.
4-(2-Benzyl-1H-benzimidazole-1-yl) aniline 6f
Yield 86.24%, mp = N.D. (Oily), colour = brown. 1H NMR
(400 MHz, DMSO-d6) dH: 3.56 (s, 2H, CH2AAr), 4.50 (s-br, 2H,
NH2), 6.35–6.38 (dd, J1 = 3.46 Hz, J2 = 9.12 Hz, 1H, PhAH), 6.48–
6.50 (dd, J1 = 3.46 Hz, J2 = 8.00 Hz, 1H, PhAH), 7.11 (s, 5H, PhAH),
7.16–7.18 (d, J = 8.20 Hz, 2H, PhAH), 7.24–7.26 (d, J = 9.12 Hz, 1H,
PhAH), 7.29–7.31 (d, J = 8.00 Hz, 1H, PhAH), 7.44–7.46 (d,
J = 8.20 Hz, 2H, PhAH). 13C NMR (100 MHz, DMSO-d6) dC: 34.9
(CH2), 115.2 (2  CH), 118.7 (2  CH), 123.4 (2  CH), 125.8,
126.2 (2  CH), 128.7 (2  CH), 129.4 (2  CH), 136.9, 138.8
(2  C), 142.7, 146.8, 148.7 ppm. kmax in nm (log emax): 230
(5.2753), 251 (5.1322), 299 (4.8401). FT-IR (mmax in cm1): 3404
(NAH interfered by OH), 2985 (CAH aliphatic), 1610 (C@C aro-
matic), 1572 (C@N). Anal. Calcd for C20H17N3 (299.37): C, 80.24;
H, 5.72; N, 14.04%. Found: C, 80.21; H, 5.90; N, 13.85%.
Antibacterial sensitivity testing of compounds 1–6f
All the synthesized compounds (1–6f) and gentamicin were
screened for antibacterial activity on four bacterial strains using
agar well diffusion method [26]. The detailed was as attached in
Supplementary Materials.Minimum inhibitory/bactericidal concentration (MIC and MBC) testing
The minimum inhibitory concentration (MIC) test on the chosen
organisms was carried out via serial dilution technique [27] and
the concentration range was from 500.00 to 15.63 mg/mL, while
the minimum bactericidal concentration (MBC) was determined
by a standard method [26]. The detailed description of the proce-
dures for the determination of MIC and MBC were as presented
in the supplementary material.Results and discussion
Based on the enthusiastic outcome of an extensive review on
functionalized benzimidazole [3] and in the continuation of the
research effort in the area of benzo-fused imidazole moieties
[6,28], the synthesis of functionalized 2-substituted and 1,2-
disubstituted benzimidazole derivatives was herein reported to
evaluate their antibacterial activities. Although, various derivatives
of benzimidazole moieties have been synthesized and reported in
literature; high temperature for the reflux process and the uses
harsh reaction condition in the presence of strong and concen-
trated acids such as HCl [4,6] have been involved. On the contrary,
the synthesis of 2-(1H-benzimizadol-2-yl)aniline precursor 1, was
achieved herein by the use of eco-friendly reaction of o-
phenylenediamine with anthranilic acid using a catalytic amount
of NH4Cl in the presence of ethyl alcohol as a solvent at refluxing
temperature of 60–70 C (Scheme 1a). The synthetic modification
of NH2 functional side chain of the reactive intermediate 1 was
conducted by reacting it with six different electrophile-releasing
substrates to furnish 2a-f. Prior to this, the reaction optimization
study was carried out using two main parameters. First, solvent
dependent condition was investigated using the synthesis of N-
(2-(1H-benzimidazole-2-yl)phenyl)acetamide 2a via the reaction
of 1 with acetyl chloride in either tetrahydrofuran (THF), ethanol
or acetonitrile at room temperature for 24 h; this gave yield of
87.7%, 30%, and 25% respectively. In addition, the thermodynamic
dependent kinetic of the synthesis of 2a was evaluated using the
comparative study of the synthesis in THF at room temperature,
60 C, and 120 C. It was unveiled that room temperature gave
the highest yield (87.71%) followed by 60 C (38.24%), while there
was no isolated product at 120 C. Thus, the same reaction condi-
tion was adopted for reaction of 1 with the remaining five
electrophile-releasing substrates b-f to produce diverse functional-
ized 2-substitutedbenzimidazole derivatives 2b-f (Scheme 1b).
According to another route [29], the o-phenylenediamine reacted
with 3,5-dinitrobenzoic acid to achieve 3 Scheme 2a, which was
subsequently treated with the earlier reported six electrophile-
releasing substrates to furnish 1,2-disubstituted benzimidazole
derivatives 4a-f (Scheme 2b) in varying yields. Finally, the last pre-
cursor 5 in this present work was prepared by the condensation of
o-phenylenediamine with phenyl acetic acid (Scheme 3a). Precur-
sor 5 was eventually reacted with the six electrophile-releasing
substrates to access the 1,2-disubstituted benzimidazole deriva-
tives 6a-f (Scheme 3b).
Physicochemical parameter data were presented in experimen-
tal section alongside the elemental analysis data. The result of ele-
mental analysis for the % calculated agreed with % found for C, H N
of all the synthesized compounds with high state of accuracy (the
difference was not more that ±0.20 in all cases). Furthermore, the
spectroscopic characterization of the targeted templates was car-
ried out using IR and UV, 1H, and 13C NMR analysis. The 1H NMR
spectra of the compounds were run in DMSO-d6 at 400 MHz with
chemical shift values recorded in ppm. The aryl-linked CH3 of 2c,
4c, and 6c resonated upfield at d 2.60–2.80 ppm as 3H singlets
and acetyl-linked CH3 of 2a, 4a, and 6awere seen upfield as 3H sin-
Scheme 1. (a) Synthesis of the precursor 1 (b) Synthesis of 2-substitutedbenzimidazoles 2a-f.
Scheme 2. (a) Synthesis of the precursor 3 (b) Synthesis of 1,2-disubstitutedbenzimidazoles 4a-f.
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well as 6a-f were noticed as singlets at d 3.42–3.73 ppm. Signals
of all aryl H appeared downfield of TMS around d 6.31–8.90 ppm,
NH2 of amine in 1, 2f, 4f, and 6f were broad singlets at d 4.50–
5.32 ppm. The most downfield signals were that of NAH of amidefound as singlets in compounds 2e, 4e, and 6e at d 11.02–
11.56 ppm. The 13C NMR spectra were run in DMSO-d6 at
100 MHz with chemical shift values recorded in ppm. On the over-
all, the 13C NMR spectra of the structure-based benzimidazole
derivatives varied from 21.3 ppm for CH3 of compound 2c to
Scheme 3. (a) Synthesis of the precursor 5 (b) Synthesis of 1,2-disubstitutedbenzimidazoles 6a-f.
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and 6c appeared at d 21.7–21.3 ppm, whereas the CH2 signals of
2d, 4d, and 6d resonated at d 48.0–48.2 ppm. The formation of
acetamide in 2a, 4a, and 6a was validated by presence of CH3
intense singlet signal at d 26.4–28.9 ppm, which was absent in
the precursors 1, 3 and 5, respectively from which they were
derived. The UV transition was run in tetrahydrofuran (THF) for
the precursors 1, 2, and 3 and their final compounds 2a-f, 4a-f,
and 6a-f. The lowest wavelengths observed at 202–224 nm, were
due to electronic excitation of p?p⁄ peculiar to C@C, which
depicted the presence of benzene ring in those structures. Batho-
chromic shifts observed herein led to the presence of other peaks
at higher wavelengths (233 nm to 470 nm). Some of these shifts
were because of p?n transition, which was attributable to the
presence of auxochromic C@N group; which belong to K bands
[28,30]. The FT-IR data of the benzimidazole derivatives 4a-f
revealed the stretching frequencies of CAH aromatic, C@C and
C@N at 3106–3050, 1622–1600, and 1580–1575 cm1, respectively
[28]. Additional bands were noticed in 2a, 4a, and 6a at 1699–
1685 cm1, which represents the C@O of amide. The two bands
at 1377–1375 and 1187–1185 cm1, which were domiciled in sul-
fonamide 2b-c, 4b-c, and 6b-c, were peculiarly assigned to SO2 func-
tionality. The bands at 1543–1540 cm1 depicted the presence of
NO2 (asym.) in compounds 3 and 4a-f. Therefore, the extrapolated
spectroscopic information of targeted benzimidazole motifs was in
concordance with the proposed structures.
Antibacterial activity
The general sensitivity testing was evaluated using the in vitro
screening of the synthesized compounds against four bacterial iso-
lates (Staphylococcus aureus, Bacillus licheniformis, Proteus vulgaris,
and Pseudomonas aeruginosa). Gentamicin was used as the positive
control in this study. The justification of gentamicin as a clinical
standard was due to the mode of action, which involved irre-
versible binding at ribosomal level, thereby signaling to obstructand interrupt protein synthesis [31]. Agar diffusion method was
used for the sensitivity testing and the diameters of zones of inhi-
bition (Z. O. I) were documented in millimeter (Table 1). Although,
large zones of inhibition were noticed for most of the targeted ben-
zimidazole derivatives final products against the screened organ-
isms, resistance was observed in few cases such as 6c against S.
aureus; 4d-f, 6a against Bacillus licheniformis; 2a, 2c, 4a, 4d, and
6f against Proteus vulgaris; 2e, 4d-f, and 6a against Pseudomonas
aeruginosa, and 6f developed resistant against the effect of gentam-
icin. Overall, the largest zone of inhibition (40.00 ± 0.10 mm) was
recorded for 1 against S. aureus,while the lowest zone of inhibition
(15.00 ± 0.08 mm) was recorded for 3 against S. aureus. In compar-
ison with gentamicin, all synthesized compounds, except 3, had
better activity with higher zones of inhibition against growth
potential of S. aureus. This means that the array of compounds syn-
thesized herein might be a possible replacement for gentamicin on
infectious disease caused by the S. aureus or enhance the potency
of gentamicin where resistance issues occur. Compared to gentam-
icin, all compounds except 3 and 6c showed larger zones of inhibi-
tion against growth of S. aureus (i.e. >16 mm); and except 4d-f and
6c against B. licheniformis (i.e. >16 mm), while 3 and 4c exhibited
approximately the same Z.O.I. as gentamicin against S. aureus
(15 mm) and B. licheniformis (16 mm), respectively. Interestingly,
more than 75% of the targeted benzimidazole derivatives were
active on P. vulgaris with large zones of inhibition, whereas this
organism was resistant to gentamicin (Table 1). Similarly, more
than 75% of the targeted benzimidazole derivatives (Z.O.
I = 25.00 ± 0.08 to 38.00 ± 0.12 mm) were more active than gen-
tamicin (20.00 ± 0.08 mm) upon P. aeruginosa. In the present study,
the choice of S. aureus and E. coli was due to the broad array of
pathogenic infections and precarious health issue that are associ-
ated with these bacterial strains [32] and wide reported occurrence
of resistant strain of S. aureus [1]. S. aureus has been reported to
have strong relationship with death rate increase in human popu-
lation, prolong admission of patients in hospitals, and the infec-
tions caused by this bacterial strain are expensive to treat [33].
Table 1
Antibacterial sensitivity testing with zones of inhibition in millimetre.
Compound No; S. aureus B. licheniformis P. vulgaris P. aeruginosa
1 40.00 ± 0.10 26.00 ± 0.08 35.00 ± 0.09 38.00 ± 0.12
2a 27.00 ± 0.09 26.00 ± 0.08 R 28.00 ± 0.08
2b 30.00 ± 0.09 20.00 ± 0.08 25.00 ± 0.09 30.00 ± 0.08
2c 35.00 ± 0.09 25.00 ± 0.08 R 28.00 ± 0.08
2d 30.00 ± 0.10 28.00 ± 0.09 30.00 ± 0.09 30.00 ± 0.09
2e 32.00 ± 0.12 26.00 ± 0.08 35.00 ± 0.08 R
2f 30.00 ± 0.11 30.00 ± 0.12 28.00 ± 0.08 30.00 ± 0.08
3 15.00 ± 0.08 20.00 ± 0.08 30.00 ± 0.12 28.00 ± 0.09
4a 20.00 ± 0.10 24.00 ± 0.09 R 25.00 ± 0.08
4b 30.00 ± 0.10 18.00 ± 0.08 20.00 ± 0.08 25.00 ± 0.08
4c 25.00 ± 0.10 16.00 ± 0.08 20.00 ± 0.08 25.00 ± 0.08
4d 30.00 ± 0.09 R R R
4e 30.00 ± 0.10 R 20.00 ± 0.08 R
4f 30.00 ± 0.12 R 23.00 ± 0.08 R
5 30.00 ± 0.09 28.00 ± 0.09 32.00 ± 0.12 38.00 ± 0.08
6a 19.00 ± 0.08 R 18.00 ± 0.08 R
6b 35.00 ± 0.09 22.00 ± 0.08 30.00 ± 0.10 28.00 ± 0.08
6c R 18.00 ± 0.08 32.00 ± 0.08 26.00 ± 0.08
6d 32.00 ± 0.10 26.00 ± 0.08 35.00 ± 0.12 30.00 ± 0.08
6e 25.00 ± 0.08 24.00 ± 0.08 25.00 ± 0.08 30.00 ± 0.09
6f 20.00 ± 0.08 26.00 ± 0.08 R 28.00 ± 0.08
Gentamicin 16.00 ± 0.09 16.00 ± 0.08 R 20.00 ± 0.08
R = Resistance. Mean ± SD of triplicate determination.
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the highly invasive organisms referred to as pyogenic cocci
involved in numerous adverse infectious conditions in humans
[28,32,34]. In view of the reported predicament aforementioned
and large zones of inhibition experienced via action of the benzim-
idazole framework herein on S. aureus, motivation was enhanced
to investigate the activity index (A.I.) of the synthesized com-
pounds against this organism (Fig. 1). It is quite impressive to note
that all the synthesized benzimidazole motifs herein, showed bet-
ter activity indices than gentamicin against S. aureus except 3 and
6c. The compound 3 competed favourably with gentamicin (A.
I.  1.00) while 6c developed resistance; hence could not have
activity index.
Furthermore, based on high susceptibility of the organisms to
the synthesized benzimidazole templates 1-6f and broad spectrum
of activity observed herein, the MIC testing was carried out to
determine the lowest concentration of the compound solution that
conveniently inhibited the bacterial growth (Table 2). It was car-
ried out using serial dilution method (500, 250, 125, 62.50, 31.25,
and 15.63 mg/mL) via an earlier reported method [27]. The MIC of
benzimidazole derivatives upon S. aureus varied from
15.63 ± 1.63 to 250 ± 2.66 mg/mL; against B. licheniformis variedFig. 1. Comparative study of the activity index offrom 62.50 ± 2.04 to 250 ± 2.65 mg/mL; against P. vulgaris varied
from 31.25 ± 1.94 to 250 ± 2.65 mg/mL; and against P. aeruginosa
ranged from 15.63 ± 1.63 to 125 ± 2.45 mg/mL. The best activity
against S. aureus was observed in the precursor 1 among the series
of the 2-substituted benzimidazoles 1-2f. The presence of amino
functionality in 1 and the ready availability of its lone pair of elec-
tron for coordination led to improved activity. The activity
decreases after the NH2 had underwent substitution as contained
in 2a-f, except for 2c and 2e, which competed favorably with 1.
This means that incorporation of p-toluenesulfonamido (in 2c)
and pyrimidinedione (in 2e) played significant role as essential
pharmacophores in increased activity observed in 2c and 2e
against S. aureus. On the contrary, the series of 1,2-disubstituted
benzimidazoles 4a-f were more active than the precursor 3 from
which they were derived. This showed that additional substitution
on position 1 of compound 3 to afford 1,2-disubstitution in 4a-f,
was a worthwhile adventure in increasing the bioactivity of pre-
cursor 3, since the series of 1,2-disubstituted benzimidazole prod-
ucts 4a-f resulted in drastic improvement of growth inhibition in S.
aureus. In addition to MIC testing, the minimum bactericidal con-
centration (MBC) testing was determined to authenticate the low-
est concentration of the benzimidazole solution that causes deathsynthesized benzimidazoles and gentamicin.
Table 2
Minimum inhibitory concentration (MIC) in mg/mL of targeted benzimidazoles, 1-6f.
Compound No; S. aureus B. licheniformis P. vulgaris P. aeruginosa
1 15.63 ± 1.64 125.00 ± 2.44 62.50 ± 2.04 31.25 ± 1.98
2a 31.25 ± 1.98 125.00 ± 2.43 N.D. 62.50 ± 2.01
2b 31.25 ± 1.97 250.00 ± 2.67 125.00 ± 2.44 31.25 ± 1.94
2c 15.63 ± 1.67 125.00 ± 2.44 N.D. 62.50 ± 2.03
2d 31.25 ± 1.96 125.00 ± 2.44 62.50 ± 2.01 62.50 ± 2.03
2e 15.63 ± 1.63 250.00 ± 2.67 62.50 ± 2.01 N.D.
2f 31.25 ± 1.94 62.50 ± 2.04 125.00 ± 2.44 31.25 ± 1.94
3 250.00 ± 2.66 250.00 ± 2.67 125.00 ± 2.44 62.50 ± 2.01
4a 125.00 ± 2.45 125.00 ± 2.44 N.D. 62.50 ± 2.02
4b 31.25 ± 1.95 250.00 ± 2.66 250.00 ± 2.67 62.50 ± 2.01
4c 62.50 ± 2.01 250.00 ± 2.66 250.00 ± 2.66 31.25 ± 1.97
4d 31.25 ± 1.98 N.D. N.D. N.D.
4e 15.63 ± 1.65 N.D. 250.00 ± 2.65 N.D.
4f 31.25 ± 1.94 N.D. 250.00 ± 2.67 N.D.
5 15.63 ± 1.67 62.50 ± 2.04 62.50 ± 2.03 15.63 ± 1.63
6a 250.00 ± 2.66 N.D. 125.00 ± 2.44 N.D.
6b 15.63 ± 1.63 250.00 ± 2.65 62.50 ± 2.04 62.50 ± 2.02
6c N.D. 250.00 ± 2.67 31.25 ± 1.94 125.00 ± 2.45
6d 31.25 ± 1.94 125.00 ± 2.44 31.25 ± 1.95 31.25 ± 1.96
6e 125.00 ± 2.45 125.00 ± 2.45 125.00 ± 2.44 62.50 ± 2.02
6f 125.00 ± 2.43 125.00 ± 2.45 N.D. 62.50 ± 2.01
Gentamicin 5.00 ± 1.23 2.5 ± 1.09 N.D. 7.5 ± 1.45
N.D. = Not Determined. Mean ± SD of triplicate determination.
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Fig. 2. Apart from where the MBC was not determined (N.D.) due
to occurrence of resistance, all other cases showed that the MBC
values were double the MIC in each consideration, except in 6a
alone where MBC (500 mg/mL) was 4 times that of MIC (125 mg/
mL) against P. vulgaris. From all indications, the lowest MBC trend
was observed for the bio-assay screening of benzimidazole deriva-
tives upon S. aureus, whereas the highest MBC was reported
against P. aeruginosa as shown in Fig. 2.Structure activity relationship (SAR) study
From the overview of the structure activity relationship (SAR)
study, it was found that the nature of substituent on 1-position
and 2-positions of the benzimidazole nucleus had significant effect
on the antibacterial activity of the entire structures. The com-
pounds series 2a-f were structurally related in the core pharma-
cophoric 2-phenylbenzimidazole; the SAR study showed their0
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Fig. 2. Graphical representation of minimactivity against S. aureus to be in the order
2c  2e > 2a  2b  2d  2f. This means that the presence of elec-
tron donating CH3 on p-toluenesulfonamide moieties in the 2-
position of anilino side chain played a significant role in the
improvement of activity, since its counterpart 2b without CH3
was far less active and stayed in the categories of 2a, 2d, and 2f
in its activity upon S. aureus growth inhibition. Considering 4a-f
on S. aureus, the activity varied in the order of:
4e > 4b  4d  4f > 4c > 4a. Thus, electron withdrawing ability
and p-p stacking character in pyrimidine-dione at 1-position of 2
-(3,5-dinitrophenyl)benzimidazole core worked synergistically
with the electron withdrawing NO2 on benzene at 2-position to
increase the activity of 4e, thereby causing it to exhibit outstanding
activity against S. aureus among the 4a-f series. Based on the
in vitro screening of 6a-f against S. aureus, the order of activity
was 6b > 6d > 6e  6f > 6a > 6c. Hence, presence of benzenesulfon-
amido group on 1-position of 2-benzylbenzimidazole in series 6a-f
played a crucial role in activity boosting, making 6b to be the most
active among the group andmore active as compared to its isomor-4C 4D 4E 4F 5 6A 6B 6C 6D 6E 6F
P. vulgaris P. aeruginosa
um bactericidal concentration (MBC).
712 O.O. Ajani et al. / Journal of Advanced Research 8 (2017) 703–712phic template 6c where no activity was noticed. It was interesting
to note that p-methyl group in 6cwhich was the only group absent
in 6b provided the framework 6a-fwith antagonistic effect thereby
causing total activity loss in 6c as compared to 6b against S. aureus.
Conclusions
Benzimidazole is an essential heterocyclic framework in agro-
chemicals, pharmaceuticals, and medicinal chemistry research.
NH4Cl catalyzed strategy was found to be efficient approach for
accessing the reported benzimidazole precursor in good yield.
Thus, mono- and disubstituted benzimidazole derivatives with
improved medicinal potential were successfully synthesized via
an elegant pathway. The findings of the in vitro screening unveiled
the broad spectrum of activity of the synthesized benzimidazole
templates in the present study. Among the series, the highest
potency was exerted and experienced in 2-(1H-benzimizadol-2-
yl)aniline, 1 and 2-benzyl-1-(phenylsulfonyl)-1H-benzimidazole,
6b. It will be a worthwhile adventure to advance the work further
for more guidance on the pharmacokinetic and pharmacodynamic
study to ascertain probable candidature of the templates for future
drug design.
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